Lv65
3180 积分 2023-03-05 加入
Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial
2天前
已完结
A phase 2a study with SPL84: A novel RNA-targeted approach to restore CFTR function in people with CF carrying the 3849+10 kb C→T mutation
16天前
已关闭
Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinoma
28天前
已完结
Antisense oligonucleotide DGAT-2 inhibitor, ION224, for metabolic dysfunction-associated steatohepatitis (ION224-CS2): results of a 51-week, multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
29天前
已完结
A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018)
29天前
已完结
Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
SHR-A2102, a nectin-4 directed antibody–drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial
1个月前
已完结
Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
2个月前
已完结
Eplontersen for Transthyretin Amyloid Cardiomyopathy
2个月前
已完结
皖公网安备34019202002308
